Combination of Nimotuzumab and Radiotherapy for Recurrent Uterine Cervical Squamous Carcinoma
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Epidermal Growth Factor Receptor
- Nimotuzumab
- Objective Response Rate
- Overall Survival
- Progression Free Survival
- Radiotherapy
- Recurrent Cervical Carcinoma
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentIntervention Model Description: All eligible patients will undergo the same treatment.Masking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Only males
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04664244
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Lei Li, M.D. Peking Union Medical College Hospital